RTI Surgical has acquired Exactech's Optecure® bone graft extender as part of a strategic partnership to expand its biologic implant portfolio.

Target Company Overview

RTI Surgical is a prominent surgical implant company that specializes in providing an extensive range of tissue-based, synthetic, and metallic implants to top-tier Original Equipment Manufacturer (OEM) clients. Recently, the company has entered into a long-term strategic partnership with Exactech, a renowned global medical device OEM, to further develop and supply biologic bone substitutes. This collaboration is set to enhance both companies' offerings in the rapidly evolving medical device market.

As a part of this strategic agreement, RTI Surgical has successfully acquired Exactech’s Optecure®, a 510(k)- cleared demineralized bone matrix. This product is specifically designed for use as a bone graft extender in various applications, including the spine, pelvis, and extremities. The inclusion of Optecure® will significantly augment RTI Surgical’s already impressive portfolio of bone graft substitutes, positioning the company for greater competitive advantage.

Industry Overview in the United States

The United States medical device industry is experiencing robust growth, driven by advancements in technology and an increasing demand for innovative surgical solutions. This sector encompasses a wide range of devices, including surgical implants and biologic materials, which are integral to improving patient outcomes. The rise in orthopedic surgeries, particularly joint replacement procedures, has exponentially increased the need for high-quality biocompatible materials.

Biologics, particularly bone graft substitutes, play a crucial role in orthopedic surgical procedures. Given the aging population and the prevalence of lifestyle-related injuries, the demand for biologic materials is expected to continue growing. These products offer significant advantages, such as reduced recovery times and enhanced healing processes, making them highly sought-after in the surgical landscape.

Furthermore, regulatory clearances, such as the 510(k) approval that Optecure® received, are vital for ensuring safety and efficacy, fostering consumer trust and expanding market opportunities for companies in this sector. Collaboration between OEMs and specialized implant manufacturers like RTI Surgical is becoming increasingly common as companies seek to leverage each other's strengths to optimize their product offerings.

This strategic partnership between RTI Surgical and Exactech is indicative of the growing trend in the medical device i